EWA
CHRS icon

EverSource Wealth Advisors’s Coherus Oncology CHRS Stock Holding History

EverSource Wealth Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.84K Sell
3,455
-125
-3% -$204 ﹤0.01% 3292
2026
Q1 		$6.05K Buy
3,580
+1,101
+44% +$1.96K ﹤0.01% 3173
2025
Q4 		$3.52K Buy
2,479
+544
+28% +$793 ﹤0.01% 3265
2025
Q3 		$3.17K Sell
1,935
-407
-17% -$453 ﹤0.01% 3343
2025
Q2 		$1.71K Buy
2,342
+749
+47% +$647 ﹤0.01% 3552
2025
Q1 		$1.29K Buy
1,593
+314
+25% +$361 ﹤0.01% 3134
2024
Q4 		$1.76K Buy
+1,279
New +$1.44K ﹤0.01% 2760

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

EverSource Wealth Advisors's CHRS Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Coherus Oncology (CHRS) stake by 3.5% in Q2 2026, selling an estimated $204 and leaving 3,455 shares worth $4.84K. The position accounts for ﹤0.01% of the portfolio, ranked #3292.

EverSource Wealth Advisors first reported a position in CHRS in Q4 2024 and has held it in 7 quarters since. The position peaked at $6.05K in Q1 2026. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • EverSource Wealth Advisors held 3,455 shares of Coherus Oncology worth $4.84K as of Q2 2026.
  • EverSource Wealth Advisors sold 125 Coherus Oncology shares in Q2 2026, an estimated $204.
  • Coherus Oncology made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3292 holding.
  • EverSource Wealth Advisors first reported a position in Coherus Oncology in Q4 2024 and has held it in 7 quarters since.
  • EverSource Wealth Advisors's Coherus Oncology position peaked at $6.05K in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.